The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
DNA repair pathways and cisplatin resistance: an intimate relationship
Open accessAbstract
The main goal of chemotherapeutic drugs is to induce massive cell death in tumors. Cisplatin is an antitumor drug widely used to treat several types of cancer. Despite its remarkable efficiency, most tumors show intrinsic or acquired drug resistance. The primary biological target of cisplatin is genomic DNA, and it causes a plethora of DNA lesions that block transcription and replication. These cisplatin-induced DNA lesions strongly induce cell death if they are not properly repaired or processed. To counteract cisplatin-induced DNA damage, cells use an intricate network of mechanisms, including DNA damage repair and translesion synthesis. In this review, we describe how cisplatin-induced DNA lesions are repaired or tolerated by cells and focus on the pivotal role of DNA repair and tolerance mechanisms in tumor resistance to cisplatin. In fact, several recent clinical findings have correlated the tumor cell status of DNA repair/translesion synthesis with patient response to cisplatin treatment. Furthermore, these mechanisms provide interesting targets for pharmacological modulation that can increase the efficiency of cisplatin chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · cited 2×
“In cases of impaired repair or excessive damage, the cells undergo apoptosis (3).”
BackgroundThe mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882 · cited 12×
“Contrary to error-free HR, the NHEJ pathway is considered an error-prone DNA repair mechanism because it may delete some nucleotides during the ligation of DSBs (49).”
BackgroundInfluentialMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“decreasing drug uptake, increasing drug efflux, and inducing drug detoxification by covalent binding to glutathione or metalloproteins (4-7) (Figure 2).”
BackgroundSystematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
DNA interstrand crosslink repair and cancer
Deans, A. J., & West, S. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3088 · Cited by 1,023
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
The Fanconi anaemia/BRCA pathway
D'Andrea, A. D., & Grompe, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc970 · Cited by 822 · cited 1×
“Furthermore, corroborating the fact that cells from FA patients are sensitive to ICL-inducing agents, there is evidence indicating that the FA/BRCA pathway participates in both ICL and DSB repair by HR (56).”
BackgroundPlatinum Resistance: The Role of DNA Repair Pathways
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 751
Lord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Lange, S. S., Takata, K.-I., & Wood, R. D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2998 · Cited by 615
The role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597
Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H. J., Hayashi, K., Groshen, S., Salonga, D., Cohen, H., Laine, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.309 · Cited by 505
Mechanisms of accurate translesion synthesis by human DNA polymerase η
Masutani, C., Kusumoto, R., Iwai, S., & Hanaoka, F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.3100 · Cited by 504
Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi, S. P., Kurdi-Haidar, B., Gordon, R. T., Cenni, B., Zheng, H., Fink, D. A., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. A., et al. (1996) · PubMed · Cited by 502
Niedernhofer, L. J., Odijk, H., Budzowska, M., van Drunen, E., Maas, A., Theil, A. F., de Wit, J., Jaspers, N. G. J., Beverloo, H. B., Hoeijmakers, J. H. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5776-5787.2004 · Cited by 492
Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486
Imai, K., & Yamamoto, H. (2008) · Carcinogenesis · doi:10.1093/carcin/bgm228 · Cited by 429
DNA resection in eukaryotes: deciding how to fix the break
Huertas, P. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1710 · Cited by 403
Mechanisms of double-strand break repair in somatic mammalian cells
Hartlerode, A. J., & Scully, R. (2009) · Biochemical Journal · doi:10.1042/bj20090942 · Cited by 365
Boulikas, T., & Vougiouka, M. (2004) · Oncology Reports · doi:10.3892/or.11.3.559 · Cited by 287
Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals
Shachar, S., Ziv, O., Avkin, S., Adar, S., Wittschieben, J., Reißner, T., Chaney, S., Friedberg, E. C., Wang, Z., Carell, T., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.281 · Cited by 284
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells
Ferry, K. V., Hamilton, T. C., & Johnson, S. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00441-x · Cited by 275
Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B., Brown, R., & on behalf of the Scottish Gynaecological Clinical Trials Group (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0732 · Cited by 262
Epigenetic lesions causing genetic lesions in human cancer
Esteller, M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00303-8 · Cited by 258
Vendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O’Connor, M. J., & Bakkenist, C. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6247 · Cited by 239
Interactions in the Error-prone Postreplication Repair Proteins hREV1, hREV3, and hREV7
Murakumo, Y., Ogura, Y., Ishii, H., Numata, S.-I., Ichihara, M., Croce, C. M., Fishel, R., & Takahashi, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102051200 · Cited by 230
Error-prone translesion synthesis mediates acquired chemoresistance
Xie, K., Doles, J., Hemann, M. T., & Walker, G. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011412107 · Cited by 219
Vaisman, A., Masutani, C., Hanaoka, F., & Chaney, S. G. (2000) · Biochemistry · doi:10.1021/bi000130k · Cited by 211
Lynch, H. T., Lynch, J. F., Lynch, P. M., & Attard, T. (2008) · Familial Cancer · doi:10.1007/s10689-007-9165-5 · Cited by 207
A Role for Polymerase η in the Cellular Tolerance to Cisplatin-Induced Damage
Albertella, M. R., Green, C. M., Lehmann, A. R., & O'Connor, M. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1095 · Cited by 207
Bypass of DNA Lesions Generated During Anticancer Treatment with Cisplatin by DNA Polymerase η
Alt, A., Lammens, K., Chiocchini, C., Lammens, A., Pieck, J. C., Kuch, D., Hopfner, K.-P., & Carell, T. (2007) · Science · doi:10.1126/science.1148242 · Cited by 203
Targeting DNA Repair Pathways for Cancer Treatment: what’s new?
Kelley, M. R., Logsdon, D., & Fishel, M. L. (2014) · Future Oncology · doi:10.2217/fon.14.60 · Cited by 202
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 199
Srivastava, A. K., Han, C., Zhao, R., Cui, T., Dai, Y., Mao, C., Zhao, W., Zhang, X., Yu, J., & Wang, Q.-E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421365112 · Cited by 188 · cited 1×
“A recent report showed elevated PolZ expression in ovarian cancer stem cells isolated from ovarian cancer cell lines and primary tumors (77).”
BackgroundTherapeutic Targeting of the DNA Mismatch Repair Pathway
Martin, S. A., Lord, C. J., & Ashworth, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0821 · Cited by 185
DNA interstrand crosslink repair in mammalian cells: step by step
Muniandy, P. A., Liu, J., Majumdar, A., Liu, S.-T., & Seidman, M. M. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409230903501819 · Cited by 179
Zheng, H., Wang, X., Warren, A. J., Legerski, R. J., Nairn, R. S., Hamilton, J. W., & Li, L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.754-761.2003 · Cited by 175
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells
Zisowsky, J., Koegel, S., Leyers, S., Devarakonda, K. R., Kassack, M. U., Osmak, M., & Jaehde, U. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.003 · Cited by 174
Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?
Bowden, N. A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.005 · Cited by 169
Lee, Y.-S., Gregory, M. T., & Yang, W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324001111 · Cited by 167
Rocha, C. R. R., Garcia, C. C. M., Vieira, D. B., Quinet, A., de Andrade-Lima, L. C., Munford, V, Belizário, J. E., & Menck, C. F. M. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.465 · Cited by 164
Self-citationDNA repair diseases: what do they tell us about Cancer and aging?
Menck, C. F., & Munford, V. (2014) · Genetics and Molecular Biology · doi:10.1590/s1415-47572014000200008 · Cited by 162
Self-citationUsanova, S., Piée-Staffa, A., Sied, U., Thomale, J., Schneider, A., Kaina, B., & Köberle, B. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-248 · Cited by 162
Li, Q., Yu, J., Mu, C., Yunmbam, M. K., Slavsky, D., Cross, C. L., Bostick-Bruton, F., & Reed, E. (2000) · PubMed · Cited by 161
Hicks, J. K., Chute, C. L., Paulsen, M. T., Ragland, R. L., Howlett, N. G., Guéranger, Q., Glover, T. W., & Canman, C. E. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00993-09 · Cited by 139
Delacôte, F., & López, B. S. (2008) · Cell Cycle · doi:10.4161/cc.7.1.5149 · Cited by 138
Johnson, S. W., Swiggard, P., Handel, L. M., Brennan, J. M., Godwin, A. K., Ozols, R. F., & Hamilton, T. C. (1994) · PubMed · Cited by 135
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
Rocha, C. R. R., Kajitani, G. S., Quinet, A., Fortunato, R. S., & Menck, C. F. M. (2016) · Oncotarget · doi:10.18632/oncotarget.10129 · Cited by 135
Self-citationDNA Repair capacity and cisplatin sensitivity of human testis tumour cells
Köberle, B., Grimaldi, K. A., Sunters, A., Hartley, J. A., Kèlland, L. R., & Masters, J. R. (1997) · International Journal of Cancer · Cited by 132
Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells
Li, Q., Gardner, K. L., Zhang, L., Tsang, B., Bostick-Bruton, F., & Reed, E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.36.23419 · Cited by 131
γH2Ax: Biomarker of Damage or Functional Participant in DNA Repair “All that Glitters Is not Gold!”
Cleaver, J. E. (2011) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2011.00995.x · Cited by 129
Park, J.-H., Long, D. T., Lee, K. Y., Abbas, T., Shibata, E., Negishi, M., Luo, Y., Schimenti, J. C., Gambus, A., Walter, J. C., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01503-12 · Cited by 128
Dependence of the Cytotoxicity of DNA-Damaging Agents on the Mismatch Repair Status of Human Cells
Papouli, E., Ćejka, P., & Jiricny, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0513 · Cited by 128
DNA Interstrand Cross-Links Induce Futile Repair Synthesis in Mammalian Cell Extracts
Mu, D., Bessho, T., Nechev, L. V., Chen, D. J., Harris, T. M., Hearst, J. E., & Sancar, A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2446-2454.2000 · Cited by 121
Wu, F., Lin, X., Okuda, T., & Howell, S. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3942 · Cited by 111
MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer
for the International Adjuvant Lung Trial-Bio investigators, Kamal, N. S., Soria, J., Mendiboure, J., Planchard, D., Olaussen, K. A., Rousseau, V., Popper, H., Pirker, R., Bertrand, P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2204 · Cited by 111
Competition, collaboration and coordination – determining how cells bypass DNA damage
Sale, J. E. (2012) · Journal of Cell Science · doi:10.1242/jcs.094748 · Cited by 109
Alagpulinsa, D. A., Ayyadevara, S., & Reis, R. J. S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00289 · Cited by 105
Inoue, A., Kikuchi, S., Hishiki, A., Shao, Y., Heath, R. J., Evison, B. J., Actis, M. L., Canman, C. E., Hashimoto, H., & Fujii, N. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.520429 · Cited by 105
Structural basis for cisplatin DNA damage tolerance by human polymerase η during cancer chemotherapy
Ummat, A., Rechkoblit, O., Jain, R., Choudhury, J. R., Johnson, R. E., Silverstein, T. D., Buku, A., Lone, S., Prakash, L., Prakash, S., et al. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2295 · Cited by 104
Jordheim, L. P., Barakat, K., Heinrich, L., Matera, E., Cros‐Perrial, E., Bouledrak, K., Sabeh, R. E., Pérez, R., Wishart, D. S., Cohen, R., et al. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.082347 · Cited by 99
Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD.
Aloyz, R. S., Xu, Z., Bello, V., Bergeron, J., Han, F., Yan, Y., Malapetsa, A., Alaoui‐Jamali, M. A., Duncan, A. M. V., & Panasci, L. (2002) · PubMed · Cited by 88
Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006842 · Cited by 87
Wang, H., Zhang, S., Wang, S., Lü, J., Wu, W., Weng, L., Chen, D., Zhang, Y., Lu, Z., Yang, H. J., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-015 · Cited by 84
Albarakati, N., Abdel-Fatah, T. M. A., Doherty, R. E., Russell, R., Agarwal, D., Moseley, P. M., Perry, C., Arora, A., Alsubhi, N. H., Seedhouse, C., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.001 · Cited by 79
Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance
McNeil, E. M., Astell, K. R., Ritchie, A., Shave, S., Houston, D. R., Bakrania, P., Jones, H. M., Khurana, P., Wallace, C., Chapman, T., et al. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.002 · Cited by 79
Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage.
Fram, R. J., Cusick, P. S., Wilson, J. M., & Marinus, M. (1985) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13467-6 · Cited by 75
Virtual Screening and Biological Evaluation of Inhibitors Targeting the XPA-ERCC1 Interaction
Barakat, K., Jordheim, L. P., Pérez, R., Wishart, D. S., Dumontet, C., & Tuszyński, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051329 · Cited by 73
Zhou, W., Chen, Y., Liu, X., Chu, P. G., Loria, S., Wang, Y., Yen, Y., & Chou, K.-M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083978 · Cited by 67
Cummings, M., Higginbottom, K., McGurk, C. J., Wong, O. G.-W., Köberle, B., Oliver, R. T. D., & Masters, J. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.04.025 · Cited by 63
Human REV1 Modulates the Cytotoxicity and Mutagenicity of Cisplatin in Human Ovarian Carcinoma Cells
Lin, X., Okuda, T., Trang, J., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020446 · Cited by 62
Olaparib in the management of ovarian cancer
Bixel, K. L., & Hays, J. L. (2015) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s62809 · Cited by 60
Mishra, A. K., Dormi, S. S., Turchi, A. M., Woods, D. S., & Turchi, J. J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.013 · Cited by 58
Burkitt, K., & Ljungman, M. E. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-24 · Cited by 57
Lin, X., Trang, J., Okuda, T., & Howell, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1380 · Cited by 55
Lerner, L. K., Francisco, G., Soltys, D. T., Rocha, C. R. R., Quinet, A., Vessoni, A. T., Castro, L. P., David, T. I. P., Bustos, S. O., Strauss, B. E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1196 · Cited by 53 · cited 1×
“Additionally, upon cisplatin treatment, PolZ was strongly induced in a P53-dependent manner (68), and it was necessary for the progression of replication”
BackgroundSelf-citationNeher, T. M., Bodenmiller, D. M., Fitch, R. W., Jalal, S. I., & Turchi, J. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0303 · Cited by 53
Sail, V., Rizzo, A. A., Chatterjee, N., Dash, R. C., Ozen, Z., Walker, G. C., Korzhnev, D. M., & Hadden, M. K. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01144 · Cited by 52
REV3L, a Promising Target in Regulating the Chemosensitivity of Cervical Cancer Cells
Yang, L., Shi, T., Liu, F., Ren, C., Wang, Z., Li, Y.-Y., Tu, X., Yang, G. S., & Cheng, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120334 · Cited by 51
Balderud, L. Z., & Bemark, M. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.03.031 · Cited by 45
Low amounts of the DNA repair XPA protein are sufficient to recover UV-resistance
Muotri, A. R., Marchetto, M. C., Suzuki, M. F., Okazaki, K., Lotfi, C. F. P., Brumatti, G., Amarante-Mendes, G. P., & Menck, C. F. M. (2002) · Carcinogenesis · doi:10.1093/carcin/23.6.1039 · Cited by 37
Self-citationLoss of hMLH1 expression correlates with improved survival in stage III–IV ovarian cancer patients
Scartozzi, M., Nictolis, M. D., Galizia, G., Carassai, P., Bianchi, F., Berardi, R., Gesuita, R., Piga, A., Cellerino, R., & Porfiri, E. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00197-7 · Cited by 33
Sokòl, A. M., Cruet-Hennequart, S., Pasero, P., & Carty, M. P. (2013) · Scientific Reports · doi:10.1038/srep03277 · Cited by 25
Burkitt, K., & Ljungman, M. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.01.017 · Cited by 24
Shi, T.-Y., Yang, L., Yang, G. S., Tu, X.-Y., Wu, X., Cheng, X., & Wei, Q. (2013) · Medical Oncology · doi:10.1007/s12032-013-0500-4 · Cited by 19
Du, P., Zhang, X., Liu, H., & Chen, L. (2015) · DNA and Cell Biology · doi:10.1089/dna.2015.2805 · Cited by 14
Cited by
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S.-H., & Chang, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 428
PRMTs and Arginine Methylation: Cancer’s Best-Kept Secret?
Jarrold, J., & Davies, C. C. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.007 · Cited by 337
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
Alhusaini, A., Cannon, A., Maher, S. G., Reynolds, J. V., & Lynam-Lennon, N. (2021) · Biomedicines · doi:10.3390/biomedicines9081024 · Cited by 24
Metadata
- Authors
- Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M.
- Venue
- Clinics
- Publisher
- Elsevier BV
- Published
- 2018
- Volume
- 73
- Issue
- suppl 1
- Pages
- e478s
- ISSN
- 1807-5932 (ISSN-L)
- OpenAlex
- W2897926526
- Cited by
- 446
- References
- 91
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.